Prevalence of Gastric Motor Dysfunction and Upper GI Symptoms in Gastric Antral Vascular Ectasias

RecruitingOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

March 22, 2024

Primary Completion Date

March 1, 2026

Study Completion Date

September 1, 2026

Conditions
Gastric Antral Vascular EctasiaCirrhosisChronic Kidney Disease
Interventions
DIAGNOSTIC_TEST

Gastric Emptying Breath Test

13C-Spirulina GEBT (Cairn Diagnostics) is non-radioactive, non-invasive breath based test validated against scintigraphy for the measurement of gastric emptying. Patients will be mailed test kits to be done in their homes remotely along with telehealth assistance from the study team. After overnight fast and providing duplicate pre-meal breath samples, the patient consumes 27 grams of re-hydrated, precisely formulated, pasteurized scrambled egg mix containing a dose of 43 mg of 13C (provided by approximately 100 mg of 13C-Spirulina), 6 saltine crackers and 6 ounces (180 mL) of potable water. The caloric value of the meal is approximately 230 kCal.Patient will provide breath samples into provided glass tubes before and after test meal administration which are then mailed back to a central laboratory for analysis by gas isotope ratio mass spectrometry.

Trial Locations (1)

55905

RECRUITING

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Cairn Diagnostics

INDUSTRY

lead

Mayo Clinic

OTHER

NCT06306963 - Prevalence of Gastric Motor Dysfunction and Upper GI Symptoms in Gastric Antral Vascular Ectasias | Biotech Hunter | Biotech Hunter